Increased FADS2 expression has been observed in certain cancers and may offer a mechanism of increased metabolic plasticity [16], suggesting increased FADS1 and/or FADS2 activity may result in therapeutic resistance in relapsed AML. This evidence concerns the gene FADS2 and acute myeloid leukemia.